CGT 360
LIVE

Serial Number

99180190

Owner

Emerging Therapy Solutions, Inc.

Attorney

Cynthia A. Moyer

Filing Date

May 12, 2025

Add to watchlist:

No watchlists yet
View on USPTO

CGT 360 Trademark

Serial Number: 99180190

CGT 360 is a trademark filed by Emerging Therapy Solutions, Inc. on May 12, 2025. The trademark is classified under Class 36 (Insurance & Financial), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

Emerging Therapy Solutions, Inc.

2001 Killebrew Drive
Bloomington, MN 55425

Entity Type: 03

Trademark Details

Filing Date

May 12, 2025

Registration Date

Not Registered

Published for Opposition

June 16, 2026

Goods & Services

Financial consultation to healthcare providers, namely, providing assistance in managing health care expenses related to cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies; Group financial risk management services, namely, health care expense risk pooling and financial risk management services related to cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies; Providing financial and insurance information and consulting in the fields of insurance and healthcare preferred provider networks relating to cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies; preferred provider network programs, namely, administration of medical services in the nature of cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies provided through a network of health care providers; Preferred provider network services, namely, administering medical benefits in the nature of cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies provided through a network of health care providers under an insurance plan

Business management and consulting services for the health care industry, namely, business management of cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies for health plans, health insurers, self-funded plans, and reinsurers; Business management and administration in the field of healthcare, namely, development, creation and implementation of health care provider networks in the field of cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies; Business administration of cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapy programs; Business data analytics services, namely, health data collection and analysis in the nature of data compiling and analyzing to provide information and metrics regarding health insurance claims to help clients forecast outcomes, business risk, and expenses; Data acquisition and collection for insurance services for business purposes; Business research in the field of health care relating to cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapy programs; Medical cost management relating to cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies.

Consulting services in the field of medical care, namely, developing medical treatment policies related to cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies; Providing medical information in the field of cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies; Concierge medical services, namely, personal health care concierge services to guide patients through medical treatments related to cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies; Medical consultations, namely, consulting, advising, and assisting patients and families with navigating the complex healthcare system relating to cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies; Providing information in the field of health care, namely, models of care, medical practice, and health care delivery and outcomes, all relating to cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies; Healthcare services, namely, provision of medical care related to cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies provided by a network of providers through an integrated, coordinated model of care delivery, with communication of best practices among the network, and the sharing of quality metrics with participants in the network; Consulting regarding healthcare services provided through an integrated and comprehensive model of care delivery featuring protocols, standards, staff training and education, implementation measures for management, care coordination, and disease management all in the field of cell and gene therapy, solid organ and bone marrow transplants, and other complex medical therapies

Filing History

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 16, 2026 NPUB
PUBLISHED FOR OPPOSITION
Jun 16, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 10, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 18, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 13, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 13, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 13, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 4, 2026 GNRN
NON-FINAL ACTION E-MAILED
May 4, 2026 GNRT
NON-FINAL ACTION WRITTEN
May 4, 2026 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Apr 29, 2026 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Apr 21, 2026 PBCR
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 29, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 9, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 9, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 9, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 26, 2025 GNRN
NON-FINAL ACTION E-MAILED
Sep 26, 2025 GNRT
NON-FINAL ACTION WRITTEN
Sep 26, 2025 CNRT
ASSIGNED TO EXAMINER
Sep 25, 2025 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Sep 21, 2025 MDSM
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 21, 2025 NWOS
APPLICATION FILING RECEIPT MAILED
May 12, 2025 MAFR
NEW APPLICATION ENTERED
May 12, 2025 NWAP